APA (7th ed.) Citation

Koh, J., & Im, S. (2026). Redefining HER2 in Breast Cancer: From Conventional Positivity to Low and Ultralow in the New Era of Antibody-Drug Conjugates. Cancer Research & Treatment, 58(1), 15. https://doi.org/10.4143/crt.2025.1182

Chicago Style (17th ed.) Citation

Koh, Jiwon, and Seock-Ah Im. "Redefining HER2 in Breast Cancer: From Conventional Positivity to Low and Ultralow in the New Era of Antibody-Drug Conjugates." Cancer Research & Treatment 58, no. 1 (2026): 15. https://doi.org/10.4143/crt.2025.1182.

MLA (9th ed.) Citation

Koh, Jiwon, and Seock-Ah Im. "Redefining HER2 in Breast Cancer: From Conventional Positivity to Low and Ultralow in the New Era of Antibody-Drug Conjugates." Cancer Research & Treatment, vol. 58, no. 1, 2026, p. 15, https://doi.org/10.4143/crt.2025.1182.